Drug resistance in non-subtype B HIV-1
- PMID: 14962783
- DOI: 10.1016/S1386-6532(03)00115-X
Drug resistance in non-subtype B HIV-1
Abstract
Treatment of HIV-1 with antiretroviral therapy may select mutations in the pol gene associated with resistance to reverse transcriptase inhibitors and protease inhibitors. To provide durable clinical benefit, emergence of drug resistance is countered by prescription of alternative drug regimens. Data on sequential treatments that are effective after virologic failure and the selection of drug resistance is largely confined to HIV-1 subtype B, the clade that has circulated in North America and Europe. However, HIV-1 subtype B currently accounts for only 12% of the estimated 40 million HIV infected individuals worldwide. The global HIV-1 epidemic includes infection with nine identified HIV-1 group M subtypes (A-K), as well as distinct sub-subtypes and numerous chimerical or recombinant forms. Increasing access to treatment of HIV-1 in the developing world and increasing non-subtype B infection through travel and migration pose new questions about the susceptibility and response of these diverse HIV-1 viruses to antiretroviral drugs. Here we review HIV diversity and the published literature on drug resistance, comparing the known resistance mutations in individuals infected with subtype B to the growing experience in the treatment of non-subtype B HIV-1 worldwide.
Similar articles
-
Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.AIDS Rev. 2003 Jan-Mar;5(1):25-35. AIDS Rev. 2003. PMID: 12875105 Review.
-
Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.Scand J Infect Dis Suppl. 2003;106:75-8. Scand J Infect Dis Suppl. 2003. PMID: 15000590 Review.
-
Antiretroviral drug resistance among HIV-1 infected children failing treatment.J Med Virol. 2002 Nov;68(3):299-304. doi: 10.1002/jmv.10203. J Med Virol. 2002. PMID: 12226814
-
Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.Virology. 2000 Sep 15;275(1):107-15. doi: 10.1006/viro.2000.0487. Virology. 2000. PMID: 11017792
-
Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.J Infect Dis. 1999 Aug;180(2):568-71. doi: 10.1086/314909. J Infect Dis. 1999. PMID: 10395885 No abstract available.
Cited by
-
Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity.J Virol. 2006 Jul;80(14):6906-16. doi: 10.1128/JVI.01900-05. J Virol. 2006. PMID: 16809296 Free PMC article.
-
Genotypic resistance testing in HIV by arrayed primer extension.Anal Bioanal Chem. 2008 Jul;391(5):1661-9. doi: 10.1007/s00216-007-1775-0. Epub 2008 Jan 18. Anal Bioanal Chem. 2008. PMID: 18202840 Free PMC article.
-
Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.AIDS. 2009 Apr 27;23(7):845-52. doi: 10.1097/QAD.0b013e328327957a. AIDS. 2009. PMID: 19276794 Free PMC article.
-
Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India.AIDS Res Treat. 2012;2012:905823. doi: 10.1155/2012/905823. Epub 2012 Mar 15. AIDS Res Treat. 2012. PMID: 22496972 Free PMC article.
-
Effects of political conflict-induced treatment interruptions on HIV drug resistance.AIDS Rev. 2013 Jan-Mar;15(1):15-24. AIDS Rev. 2013. PMID: 23449225 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
